{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:41:11Z","timestamp":1792428071403,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"vor","delay-in-days":90,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100017607","name":"Shenzhen Fundamental Research Program","doi-asserted-by":"publisher","award":["JCYJ20240813150249044, JCYJ20250604143756074"],"award-info":[{"award-number":["JCYJ20240813150249044, JCYJ20250604143756074"]}],"id":[{"id":"10.13039\/501100017607","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Guangdong Basic and Applied Basic Research Foundation","award":["2023A1515030058"],"award-info":[{"award-number":["2023A1515030058"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08666-1","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T16:53:04Z","timestamp":1784652784000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CD73-LNPs promote antitumor T-cell immunity via amplifying TLR3-mediated immunostimulatory dendritic cell activation"],"prefix":"10.1186","volume":"24","author":[{"given":"Yuandong","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haowei","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunru","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze-Xiu","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gao-Feng","family":"Zha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0024-9415","authenticated-orcid":false,"given":"Jun","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"8666_CR1","doi-asserted-by":"publisher","first-page":"e450","DOI":"10.1016\/S1470-2045(22)00372-2","volume":"23","author":"CL Lorentzen","year":"2022","unstructured":"Lorentzen CL, Haanen JB, Met \u00d6, Svane IM. Clinical advances and ongoing trials on mRNA vaccines for cancer treatment. Lancet Oncol. 2022;23:e450\u20138.","journal-title":"Lancet Oncol"},{"key":"8666_CR2","doi-asserted-by":"publisher","first-page":"100562","DOI":"10.1016\/j.medj.2024.11.015","volume":"6","author":"AV Yaremenko","year":"2025","unstructured":"Yaremenko AV, Khan MM, Zhen X, Tang Y, Tao W. Clinical advances of mRNA vaccines for cancer immunotherapy. Med. 2025;6:100562.","journal-title":"Med"},{"key":"8666_CR3","doi-asserted-by":"publisher","first-page":"217752","DOI":"10.1016\/j.canlet.2025.217752","volume":"625","author":"H Li","year":"2025","unstructured":"Li H, Min L, Du H, Wei X, Tong A. Cancer mRNA vaccines: clinical application progress and challenges. Cancer Lett. 2025;625:217752.","journal-title":"Cancer Lett"},{"key":"8666_CR4","doi-asserted-by":"crossref","unstructured":"Floudas CS, Sarkizova S, Ceccarelli M, Zheng W. Leveraging mRNA technology for antigen based immuno-oncology therapies. J Immunother Cancer. 2025;13.","DOI":"10.1136\/jitc-2024-010569"},{"key":"8666_CR5","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/s41571-024-00902-1","volume":"21","author":"EJ Sayour","year":"2024","unstructured":"Sayour EJ, Boczkowski D, Mitchell DA, Nair SK. Cancer mRNA vaccines: clinical advances and future opportunities. Nat Rev Clin Oncol. 2024;21:489\u2013500.","journal-title":"Nat Rev Clin Oncol"},{"key":"8666_CR6","doi-asserted-by":"crossref","unstructured":"Cui M, Ma S, Huang Z, Zhang D, Sun X, You Y. Medicinal chemistry strategies for the development of CD73 inhibitors in cancer immunotherapy. Med Res Rev. 2025.","DOI":"10.1002\/med.70029"},{"key":"8666_CR7","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s43556-025-00345-9","volume":"6","author":"J Shen","year":"2025","unstructured":"Shen J, Liao B, Gong L, Li S, Zhao J, Yang H, et al. CD39 and CD73: biological functions, diseases and therapy. Mol Biomed. 2025;6:97.","journal-title":"Mol Biomed"},{"key":"8666_CR8","doi-asserted-by":"publisher","first-page":"23001","DOI":"10.1021\/acsnano.4c04553","volume":"18","author":"H Zhang","year":"2024","unstructured":"Zhang H, Yang L, Han M, Han Y, Jiang Z, Zheng Q, et al. Boost Infiltration and Activity of T Cells via Inhibiting Ecto-5\u2019-nucleotidase (CD73) Immune Checkpoint to Enhance Glioblastoma Immunotherapy. ACS Nano. 2024;18:23001\u201313.","journal-title":"ACS Nano"},{"key":"8666_CR9","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.7150\/thno.91119","volume":"14","author":"Y Deng","year":"2024","unstructured":"Deng Y, Chen Q, Yang X, Sun Y, Zhang B, Wei W, et al. Tumor cell senescence-induced macrophage CD73 expression is a critical metabolic immune checkpoint in the aging tumor microenvironment. Theranostics. 2024;14:1224\u201340.","journal-title":"Theranostics"},{"key":"8666_CR10","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1038\/s43587-025-00966-3","volume":"5","author":"M Bodogai","year":"2025","unstructured":"Bodogai M, Park B, Braikia FZ, Naqing F, Kumaraswami K, Chen C, et al. A distinct population of CD8(+) T cells expressing CD39 and CD73 accumulates with age and supports cancer progression. Nat Aging. 2025;5:2055\u201369.","journal-title":"Nat Aging"},{"key":"8666_CR11","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1172\/JCI128895","volume":"130","author":"SY Neo","year":"2020","unstructured":"Neo SY, Yang Y, Record J, Ma R, Chen X, Chen Z, et al. CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment. J Clin Invest. 2020;130:1185\u201398.","journal-title":"J Clin Invest"},{"key":"8666_CR12","doi-asserted-by":"crossref","unstructured":"Klysz DD, Fowler C, Malipatlolla M, Stuani L, Freitas KA, Chen Y, et al. Inosine induces stemness features in CAR-T cells and enhances potency. Cancer Cell. 2024;42:266\u201382.e8.","DOI":"10.1016\/j.ccell.2024.01.002"},{"key":"8666_CR13","doi-asserted-by":"publisher","first-page":"e2302691","DOI":"10.1002\/adhm.202302691","volume":"13","author":"Y Xu","year":"2024","unstructured":"Xu Y, Hu Y, Xia H, Zhang S, Lei H, Yan B, et al. Delivery of mRNA Vaccine with 1, 2-Diesters-Derived Lipids Elicits Fast Liver Clearance for Safe and Effective Cancer Immunotherapy. Adv Healthc Mater. 2024;13:e2302691.","journal-title":"Adv Healthc Mater"},{"key":"8666_CR14","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1186\/s12951-025-03607-4","volume":"23","author":"F Cao","year":"2025","unstructured":"Cao F, Xu Y, Guan Y, Zhang K, Qiu H, Xu Z, et al. Enhancing the potency of 5T4 mRNA vaccine by CD70 mRNA-LNPs through ADCC and T cell boosting in prostate cancer therapy. J Nanobiotechnol. 2025;23:523.","journal-title":"J Nanobiotechnol"},{"key":"8666_CR15","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1038\/s41422-025-01186-5","volume":"35","author":"Y Sun","year":"2025","unstructured":"Sun Y, Zhang Z, Li H, Bu X, Chen L, Wang X, et al. Destruction of VISTA by TRIM25 ablation in T cells potentiates cancer immunotherapy. Cell Res. 2025;35:1003\u201320.","journal-title":"Cell Res"},{"key":"8666_CR16","doi-asserted-by":"crossref","unstructured":"Huber F, Bassani-Sternberg M. Defects in antigen processing and presentation: mechanisms, immune evasion and implications for cancer vaccine development. Nat Rev Immunol. 2025.","DOI":"10.1038\/s41577-025-01208-8"},{"key":"8666_CR17","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/s41467-024-44787-1","volume":"15","author":"CYC Lee","year":"2024","unstructured":"Lee CYC, Kennedy BC, Richoz N, Dean I, Tuong ZK, Gaspal F, et al. Tumour-retained activated CCR7(+) dendritic cells are heterogeneous and regulate local anti-tumour cytolytic activity. Nat Commun. 2024;15:682.","journal-title":"Nat Commun"},{"key":"8666_CR18","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/s41563-018-0077-6","volume":"17","author":"EA Gosselin","year":"2018","unstructured":"Gosselin EA, Eppler HB, Bromberg JS, Jewell CM. Designing natural and synthetic immune tissues. Nat Mater. 2018;17:484\u201398.","journal-title":"Nat Mater"},{"key":"8666_CR19","doi-asserted-by":"publisher","first-page":"e2300351","DOI":"10.1002\/adhm.202300351","volume":"12","author":"X He","year":"2023","unstructured":"He X, Wang J, Tang Y, Chiang ST, Han T, Chen Q, et al. Recent Advances of Emerging Spleen-Targeting Nanovaccines for Immunotherapy. Adv Healthc Mater. 2023;12:e2300351.","journal-title":"Adv Healthc Mater"},{"key":"8666_CR20","doi-asserted-by":"publisher","first-page":"114591","DOI":"10.1016\/j.celrep.2024.114591","volume":"43","author":"Z Xu","year":"2024","unstructured":"Xu Z, Ma W, Wang J, Chen H, Li H, Yin Z, et al. Nuclear HMGB1 is critical for CD8 T cell IFN-\u03b3 production and anti-tumor immunity. Cell Rep. 2024;43:114591.","journal-title":"Cell Rep"},{"key":"8666_CR21","doi-asserted-by":"crossref","unstructured":"van der Sluis TC, van Haften FJ, van Duikeren S, Pardieck IN, de Graaf JF, Vleeshouwers W, et al. Delayed vaccine-induced CD8(+) T cell expansion by topoisomerase I inhibition mediates enhanced CD70-dependent tumor eradication. J Immunother Cancer. 2023;11.","DOI":"10.1136\/jitc-2023-007158"},{"key":"8666_CR22","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41585-024-00900-z","volume":"22","author":"MK Bakht","year":"2025","unstructured":"Bakht MK, Beltran H. Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer. Nat Rev Urol. 2025;22:26\u201345.","journal-title":"Nat Rev Urol"},{"key":"8666_CR23","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.eururo.2025.02.001","volume":"87","author":"C Hage Chehade","year":"2025","unstructured":"Hage Chehade C, Ozay ZI, Ostrowski M, Mercinelli C, Gebrael G, Sayegh N, et al. T-cell Engagers in Prostate Cancer. Eur Urol. 2025;87:553\u20138.","journal-title":"Eur Urol"},{"key":"8666_CR24","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41568-023-00635-w","volume":"24","author":"TR Mempel","year":"2024","unstructured":"Mempel TR, Lill JK, Altenburger LM. How chemokines organize the tumour microenvironment. Nat Rev Cancer. 2024;24:28\u201350.","journal-title":"Nat Rev Cancer"},{"key":"8666_CR25","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.immuni.2024.03.004","volume":"57","author":"T Kawai","year":"2024","unstructured":"Kawai T, Ikegawa M, Ori D, Akira S. Decoding Toll-like receptors: Recent insights and perspectives in innate immunity. Immunity. 2024;57:649\u201373.","journal-title":"Immunity"},{"key":"8666_CR26","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1038\/s41467-021-23244-3","volume":"12","author":"J Koerner","year":"2021","unstructured":"Koerner J, Horvath D, Herrmann VL, MacKerracher A, Gander B, Yagita H, et al. PLGA-particle vaccine carrying TLR3\/RIG-I ligand Riboxxim synergizes with immune checkpoint blockade for effective anti-cancer immunotherapy. Nat Commun. 2021;12:2935.","journal-title":"Nat Commun"},{"key":"8666_CR27","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.3389\/fimmu.2017.01897","volume":"8","author":"M Matsumoto","year":"2017","unstructured":"Matsumoto M, Takeda Y, Tatematsu M, Seya T. Toll-Like Receptor 3 Signal in Dendritic Cells Benefits Cancer Immunotherapy. Front Immunol. 2017;8:1897.","journal-title":"Front Immunol"},{"key":"8666_CR28","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41392-023-01674-3","volume":"8","author":"T Fan","year":"2023","unstructured":"Fan T, Zhang M, Yang J, Zhu Z, Cao W, Dong C. Therapeutic cancer vaccines: advancements, challenges, and prospects. Signal Transduct Target Ther. 2023;8:450.","journal-title":"Signal Transduct Target Ther"},{"key":"8666_CR29","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.ccell.2020.07.013","volume":"38","author":"V Leko","year":"2020","unstructured":"Leko V, Rosenberg SA. Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors. Cancer Cell. 2020;38:454\u201372.","journal-title":"Cancer Cell"},{"key":"8666_CR30","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41392-024-01868-3","volume":"9","author":"M Yi","year":"2024","unstructured":"Yi M, Li T, Niu M, Zhang H, Wu Y, Wu K, et al. Targeting cytokine and chemokine signaling pathways for cancer therapy. Signal Transduct Target Ther. 2024;9:176.","journal-title":"Signal Transduct Target Ther"},{"key":"8666_CR31","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.immuni.2021.01.012","volume":"54","author":"AJ Ozga","year":"2021","unstructured":"Ozga AJ, Chow MT, Luster AD. Chemokines and the immune response to cancer. Immunity. 2021;54:859\u201374.","journal-title":"Immunity"},{"key":"8666_CR32","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1016\/j.immuni.2023.06.003","volume":"56","author":"MA Moreno Ayala","year":"2023","unstructured":"Moreno Ayala MA, Campbell TF, Zhang C, Dahan N, Bockman A, Prakash V, et al. CXCR3 expression in regulatory T cells drives interactions with type I dendritic cells in tumors to restrict CD8(+) T cell antitumor immunity. Immunity. 2023;56:1613\u2013e305.","journal-title":"Immunity"},{"key":"8666_CR33","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1016\/j.immuni.2023.07.018","volume":"56","author":"LL Cao","year":"2023","unstructured":"Cao LL, Kagan JC. Targeting innate immune pathways for cancer immunotherapy. Immunity. 2023;56:2206\u201317.","journal-title":"Immunity"},{"key":"8666_CR34","doi-asserted-by":"crossref","unstructured":"Zhang H, You X, Wang X, Cui L, Wang Z, Xu F, et al. Delivery of mRNA vaccine with a lipid-like material potentiates antitumor efficacy through Toll-like receptor 4 signaling. Proc Natl Acad Sci U S A. 2021;118.","DOI":"10.1073\/pnas.2005191118"},{"key":"8666_CR35","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1038\/s41587-019-0247-3","volume":"37","author":"L Miao","year":"2019","unstructured":"Miao L, Li L, Huang Y, Delcassian D, Chahal J, Han J, et al. Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation. Nat Biotechnol. 2019;37:1174\u201385.","journal-title":"Nat Biotechnol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08666-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08666-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08666-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:02:36Z","timestamp":1792425756000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08666-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8666"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08666-1","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"assertion":[{"value":"4 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Institutional Animal Care and Use Committee (IACUC) at Sun Yat-Sen University has formally approved all the animal procedures (SYSU-IACUC-2025-002827).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have read and approved the manuscript.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1317"}}